Cross-Sector entity
Takeda Pharmaceutical is most often covered alongside CSL Behring, which appears in 2 of these 3 stories. That works out to roughly 0.8 stories per week across a 26-day span. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category.
3 verified stories tracked
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Takeda Pharmaceutical is most often covered alongside CSL Behring, which appears in 2 of these 3 stories. That works out to roughly 0.8 stories per week across a 26-day span. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Takeda Pharmaceutical appears in 3 tracked Cross-Sector stories published from February 20, 2026 through March 17, 2026. The tracked stories average 2 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Takeda Pharmaceutical. Shared-story counts are live from our verified record — not editorial picks.
Market Peak
Projected valuation of $25.15 billion reached through global capacity expansion.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
Current Milestone
Market valuation hits significant mid-term growth targets as supply meets latent demand.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Infrastructure Investment
Major fractionators announce multi-billion dollar investments in automated collection centers.
Supply Recovery
Plasma collection volumes begin to stabilize following pandemic-era disruptions.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by massive investments in plasma collection infrastructure and rising demand for primary immunodeficiency treatments. This growth reflects a stabilization of the supply chain following pandemic-era disruptions and a strategic shift toward subcutaneous delivery methods.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by a significant expansion in plasma collection infrastructure. This growth reflects rising clinical demand for antibody therapies and improved supply chain efficiencies across major pharmaceutical hubs.
Source: portal.sina.com.hk · manilatimes.net
